# Belatacept in Renal Transplantation With Intermediate Risk Maryland Aggregate Pathology Index (MAPI) Scores

> **NCT01496417** · NA · COMPLETED · sponsor: **University of Maryland** · enrollment: 20 (actual)

## Conditions studied

- End-Stage Renal Disease

## Interventions

- **DRUG:** Belatacept

## Key facts

- **NCT ID:** NCT01496417
- **Lead sponsor:** University of Maryland
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2017-02-28
- **Final completion:** 2018-03-01
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2018-06-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01496417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01496417, "Belatacept in Renal Transplantation With Intermediate Risk Maryland Aggregate Pathology Index (MAPI) Scores". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT01496417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*